IPSC logo

CENTURY THERAPEUTICS INC

IPSCNASDAQ
🏆 #3888 by market capEarnings Nov 11 · PreUS Equity
$1.65▼ $0.01 (−0.90%)
After hours · at close
🔔
Track IPSC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d▼ 13.9%
14d▼ 16.9%
30d▼ 18.8%
ytd▲ 68.5%
1y▲ 230.6%
🏦Market Cap
$142M
Small Cap
📈Revenue Growth (YoY)
+1556.8%
High Growth
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
48
Weak

Trading Snapshot

Day Range
$1.63 – $1.67
52-Week Range
$0.44 – $3.04
Volume
$1.58B
Avg Volume
$1.90B
Shares Outstanding
86.6M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$109M
Last Q Revenue
$25M
P/E Ratio
-1.6
P/S Ratio
0.0x
EPS (TTM)
$-0.53
Dividend Yield
0.00%
Dilution (1yr)
+10.1%

Why Investors Own IPSC

  • ✓High-growth profile — revenue up +8.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 60% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IPSC logo

CENTURY THERAPEUTICS INC

IPSC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$109M▲ +1556.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.0%▼ −12.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▼ −89.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$105M▼ −5.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
86.6M▲ +10.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$18M▲ +$14M YoY
StockOtter · stockotter.space

About CENTURY THERAPEUTICS INC

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$2.00
▲ +21.3% Upside
High Target$2.20
Low Target$1.69
Based on 12 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

CENTURY THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift IPSC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CENTURY THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.